Robert W. Baird analyst Jeff Johnson maintained a Buy rating on Dexcom (NASDAQ:DXCM) on Tuesday, setting a price target of $460, which is approximately 17.96% above the present share price of $389.95.
Johnson expects Dexcom to post earnings per share (EPS) of $0.42 for the second quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Strong Buy rating of shares in Dexcom, with an average price target of $466.83.
The analysts price targets range from a high of $500 to a low of $380.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $505 million and a net profit of $45.9 million. The company's market cap is $37.71 billion.
According to TipRanks.com, Robert W. Baird analyst Jeff Johnson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 29.9% and a 71.02% success rate.
California-based DexCom , Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.